The Blueprint Audit: What 70 Pills a Day Actually Buys

LONGEVITY LATEST ISSUE 13 · 3 JUNE 2026

LONGEVITY LATEST

The Evidence-Based Edge on Living Longer and Better

Issue 13 · The Blueprint Audit: What 70 Pills a Day Actually Buys · 3 June 2026

Subject line A: Bryan Johnson's best result isn't the famous one 🧬

Subject line B: 70 pills, three that earn their place

Preview text: The famous ageing-clock number isn't the win — the boring biomarker underneath it is. We audited the stack.

WELCOME

👋 Welcome

One man takes seventy-plus pills a day, publishes the receipts, the bloods, the DEXA scans — and has told the internet his pace of ageing has slowed by 31 years. Here is the strangest thing this week's audit turned up: his most famous result is also his weakest, and his strongest result is the one he almost never leads with.

This issue is really about measurement versus marketing. Blueprint isn't one thing — it's diet, exercise, sleep, testing, supplements, and a personal brand, stacked together. The hard work is separating the parts that change a body from the parts that just generate clicks. We graded three pills, ran the price comparison, and put the consumer ageing-clock industry on the table. The verdict to the central question — what the protocol can prove it actually did — lives in this week's Deep Dive.

In this issue:

• 🔬 Top 3: Extra-virgin olive oil, lithium orotate, collagen peptides — graded

• ⭐ Spotlight: £4 multivitamin vs £400 personalised stack — what COSMOS actually showed

• 🚨 Hype Check: "Your biological age is 38" — the consumer-clock noise floor

• 📖 Deep Dive: Bryan Johnson's best result is the one he doesn't lead with

• 🌾 Superfood: Sardines — £1.20 worth of what three Blueprint capsules try to deliver

• 🌡 Biohacking Corner: Track like Blueprint, on £0

THIS WEEK'S ANALYSIS

🔬 Top 3 Interventions Under the Microscope

Three pills from the seventy, picked to span the evidence curve. Grades sit on a hierarchy worth keeping in mind: RCT (randomised trial in humans) beats cohort (observational at scale) beats mechanism (pre-clinical, plausible) beats n-of-1 (one well-tracked person — interesting, not generalisable).

1. Extra-virgin olive oil (high-polyphenol) — Evidence Grade: A

What it is. A whole-food fat — Blueprint's daily 30 ml is the protocol's quiet workhorse. The pharmacologically interesting bits are oleocanthal, oleuropein, and hydroxytyrosol — phenolics in the unrefined oil, mostly destroyed by heat-extraction. "Light" or "pure" olive oil isn't the same molecule.

Human evidence. Cohort + RCT. Tessier et al. (JAMA Network Open 2024) followed 92,383 US adults for up to 28 years and found ≥7 g/day of olive oil associated with a 28% lower risk of dementia-related death versus rare or no consumption — and the protection survived adjustment for diet quality and dementia-risk genetics. That signal shouldn't survive 28 years of confounders if it weren't real. PREDIMED is the RCT foundation: a Mediterranean diet with extra-virgin olive oil cut major cardiovascular events by ~30% over five years (Estruch et al., NEJM 2018).

Cautions. Half the supermarket "extra virgin" on UK shelves fails phenolic-content testing — look for an early harvest date, dark glass, and a peppery throat burn (that's the oleocanthal). Calorie-dense; substitute for other fats, don't pile on top.

Takeaway. The most consistent diet-derived signal in healthy ageing, replicated across observational and randomised work. Boring, food, cheap — and almost certainly the most effective bottle on Bryan's worktop. Evidence Grade A.

2. Lithium orotate (microdose) — Evidence Grade: B−

What it is. A trace mineral the brain runs on, added to Blueprint in 2026 after a decade of pre-clinical signal. The orotate salt crosses into brain at lower doses than the carbonate used in psychiatry — typically 1–5 mg of elemental lithium, not the 600 mg+ in a bipolar prescription.

Human evidence. Mechanism + cohort, contradicted by one small RCT. The mechanism story just got a Nature cover: Aron et al. (Yankner lab, Harvard, August 2025) showed amyloid plaques sequester the brain's available lithium, and low-dose lithium orotate reversed memory decline in mouse models at doses an order of magnitude below psychiatric ones. A 2024 meta-analysis put long-term lithium exposure at a 41% lower risk of Alzheimer's (RR 0.59).

Then came LATTICE. The pilot RCT of low-dose lithium in mild cognitive impairment did not slow decline at the doses used. Striking mechanism, robust cohort signal, negative human trial — read in that order, it's the most interesting drug on Bryan's table.

Cautions. Thyroid and kidney function need monitoring at microdoses if you take it daily for years. SSRIs, NSAIDs, ACE inhibitors and diuretics all push lithium levels around — this is a conversation with a prescriber, not an influencer.

Takeaway. The molecule most likely to be either huge or a footnote in five years. I'd rather watch a phase 3 from a Harvard team than guess from my kitchen. Evidence Grade B−: real signal, premature for self-prescription.

3. Collagen peptides — Evidence Grade: C+

What it is. Hydrolysed collagen — short peptide chains the gut absorbs. Blueprint ships its own; Bryan takes ~25 g daily.

Human evidence. RCTs with a funding tell. Khor et al. (American Journal of Medicine 2025) pooled 23 RCTs across 1,474 participants and reported improvements in skin hydration, elasticity, and wrinkles — but when they stratified, industry-funded trials showed the effect, independently funded ones didn't, and high-quality studies showed no elasticity effect at all. That pattern is more diagnostic than the headline. There is no human evidence the stuff moves joint outcomes, bone density, or any biomarker a clock or DEXA would notice.

Takeaway. If you're tracking glow, the cheap stuff at 10 g/day is fine and probably mostly placebo. Evidence Grade C+ for skin, F for the rest of the marketing.

SPOTLIGHT

⭐ Spotlight Treatment: A £4 Multivitamin vs a £400 Personalised Stack

The contrast is the whole point: the generic multivitamin has actual trial data; the personalised stack has plausible logic and no protocol-level RCT. Hold those two facts together and the £400 premium gets harder to defend.

RCT. COSMOS — three substudies across ~5,200 participants, 2022–2024 — randomised older adults to a daily Centrum Silver or placebo. The meta-analysis showed roughly 60% slower global cognitive ageing over three years, with the equivalent of about 1.8 years recovered. Not a perfect trial. But the largest, longest, blinded test of "should I take a multivitamin?" we have, and it points one way.

The £400 personalised stack has zero RCTs at its specific dosing protocol. That's not the same as "the components don't work" — some do, individually. It means the combination, at those doses, in that population, has never been tested as a unit. Every component is sold on its weakest member's trial, and "personalisation" is mostly downstream of bloods with reference ranges built for disease screening, not optimisation.

Pros (of the personalised approach)

✓ Forces you to look at your bloods, which most people never do.

✓ Can correct genuine deficiencies a generic dose underplays — vitamin D at 50° latitude is the obvious one.

✓ Occasionally catches a hidden problem (low ferritin, undiagnosed thyroid) the stack didn't promise but solves.

Cons

⚠ No RCT evidence the stack outperforms a generic multivitamin on any meaningful endpoint.

⚠ "Personalisation" usually means upselling — almost no service tells you to take fewer pills.

⚠ Circular evidence: a study on ingredient X in healthy 65-year-olds is sold as relevant to a 40-year-old on a fifteen-component stack at unstudied combined doses.

HYPE CHECK

🚨 Hype Check: "Your Biological Age Is 38"

The Hype. A spit kit comes back with a number — biologically, you're 38. Take the stack. Retest in six months. Watch yourself get younger. TruDiagnostic, myDNAge, and a clutch of cheaper retailers have built an industry on selling that loop.

The Evidence. Higgins-Chen et al. (Nature Aging 2022) ran the canonical clocks twice on the same blood sample. The biggest clocks deviated by up to 9 years between replicates from technical noise alone. Their fix — principal-component versions — got that down to under 1.5 years, but most consumer reports don't disclose which version they use. A separate analysis of one major provider estimated about a 42% margin of error for detecting individual change. Sit with that for a second. You spend £400 on a stack, retest, get a result two years younger — and roughly half the time, that's the measurement, not you.

Why It's Misleading. Aggregate trials use these clocks correctly — large groups, repeated samples, defensible statistics. A solo person, two draws, a number to brag about: that's the use case the marketing leans on and the science doesn't support. (Whether Bryan Johnson's own clock data clears that bar — given he's an n of one — is the question the Deep Dive settles.)

SUPERFOOD

🌾 Superfood Spotlight: Sardines

After a section on £400 stacks, a tin of fish. A 120 g tin of sardines in olive oil delivers, in one go: ~23 g of protein, 1.5–2 g of EPA + DHA, 80% of a day's vitamin D, two-thirds of a day's selenium, more calcium than a glass of milk (the bones), and B12 well above daily.

The Mediterranean and Adventist Health cohorts have shown repeatedly that oily fish two to three times a week tracks with the cleanest cardiovascular and dementia signals in nutritional epidemiology. The fish oil on Bryan's protocol is a $40-a-month proxy for £4 worth of sardines.

A tin from Tesco costs about £1.20. Two tins a week would cover most of what three Blueprint capsules try to deliver (protein, omega-3, vitamin D, selenium) at one-fifteenth the cost. Bring olives.

DEEP DIVE

📖 Deep Dive — Bryan Johnson's Best Result Is the One He Doesn't Lead With

Here is the question this whole issue has been circling and the email cannot fully settle. The famous claim — pace of ageing slowed by 31 years, DunedinPACE 0.69, biologically 18 on some organs — runs straight into the noise floor we just described in the Hype Check. So which of Bryan's published numbers actually clear that bar, and which don't?

The Deep Dive opens the spreadsheet. It separates the n-of-one structural ceiling on the clock numbers from the win his own data does support — and explains why the boring biomarker underneath the t-shirt is the one your future self will actually feel. If you read one thing this week, read this:

👉 The verdict to the issue is here: Bryan Johnson's Best Result Is the One He Doesn't Lead With

1,420 words · 7-minute read

BIOHACKING CORNER

🌡 Biohacking Corner: Track Like Blueprint, on £0

Most of Blueprint's actual value isn't the pills. It's the measurement. The protocol forces a person to write down what they ate, how they slept, what their resting heart rate did this week — and then look at it. Almost nobody does this.

You can run a meaningful version of the same loop with what's on your phone and on the NHS — be the one person in your GP surgery who turns up with three months of trend data instead of last week's symptoms.

1. Annual NHS bloods — screenshot them. Lipid panel, HbA1c, vitamin D, ferritin, TSH, B12 — most are routine if you ask. Drop the values into a free spreadsheet. Year-on-year change is the most underused diagnostic in adult medicine.

2. One wearable, one metric. Don't track twenty things. Pick resting heart rate or HRV and watch a six-week rolling average. You'll see, almost immediately, what Friday's wine costs you on Sunday.

3. Body composition, not weight. A £20 caliper or a £35 home bioimpedance scale won't match a DEXA, but it'll catch the direction.

A month of this beats a month of the Blueprint stack at zero cost. At the end of it, you'll know whether you actually need the stack. Most people won't.

READER PULSE

📊 Reader Pulse

Last issue's GLP-1 poll drew near-record turnout. The largest bracket — about 30% — was "considering it for myself or a family member," nudging out the prescribed-via-mainstream group at 27%. Privately sourced or compounded held steady around 8% (progress, post-Hype Check). One reader's email summed up the mood: "I'd consider it if my GP would discuss it without rolling her eyes." That sentence is the entire NHS gap in fifteen words.

This week's question:

If money were no object, would you actually run the Blueprint protocol?

• Yes — full stack, full measurement

• The measurement parts, none of the pills

• A few of the pills, on my own bloods

• Neither — boring fundamentals are enough

• Already do a version of this

👉 Vote at longevitylatest.com/poll-13

CLOSING

🎯 Closing

The Blueprint takeaway isn't that the pills don't work — it's that the protocol's value sits in the parts nobody copies. The bloods, the measurement, the discipline of writing it down. Most of the seventy pills are background noise to one extremely well-tracked life.

Issue 14: cold exposure. Ice baths, £40 plunge studios, whether any of it earns the YouTube hype — versus the one cold protocol with tight RCT data behind it. Plus a Hype Check on a wearable promising to "measure inflammation."

Stay curious and stay healthy!

— Christian Thomsen, Editor

Longevity Latest is published weekly by FrontWave Media Ltd. The content is for educational purposes and does not constitute medical advice. Lithium supplementation, even at microdoses, requires medical supervision — particularly if taking SSRIs, NSAIDs, ACE inhibitors, or diuretics. Consult your physician before starting any new supplement regimen, especially if you are pregnant, nursing, or managing a chronic condition.

© 2026 FrontWave Media Ltd · Longevity Latest